Akari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNH
Jan 03, 2017 12:01 pm UTC| Business
NEW YORK and LONDON, Jan. 03, 2017 -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has allowed on...
Akari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNH
Jan 03, 2017 12:01 pm UTC| Business
NEW YORK and LONDON, Jan. 03, 2017 -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has allowed on...
AxoGen to Participate at AAHS ASPN ASRM Joint 2017 Annual Meeting
Jan 03, 2017 12:01 pm UTC| Business
ALACHUA, Fla., Jan. 03, 2017 -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative surgical solutions for peripheral nerve injuries, today announced its participation at the joint 2017 Meeting of the American...
AxoGen to Participate at AAHS ASPN ASRM Joint 2017 Annual Meeting
Jan 03, 2017 12:01 pm UTC| Business
ALACHUA, Fla., Jan. 03, 2017 -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative surgical solutions for peripheral nerve injuries, today announced its participation at the joint 2017 Meeting of the American...
Anavex Life Sciences Obtains Permanent Dismissal of All Claims in Securities Lawsuit
Jan 03, 2017 12:01 pm UTC| Business
NEW YORK, Jan. 03, 2017 -- Anavex Life Sciences Corp. (Nasdaq:AVXL) a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental...
Anavex Life Sciences Obtains Permanent Dismissal of All Claims in Securities Lawsuit
Jan 03, 2017 12:01 pm UTC| Business
NEW YORK, Jan. 03, 2017 -- Anavex Life Sciences Corp. (Nasdaq:AVXL) a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental...
Jan 03, 2017 12:01 pm UTC| Business
DEVON, Pa., Jan. 03, 2017 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today...